AI Article Synopsis
- Radiofrequency ablation (RFA) is an effective minimally invasive treatment for renal tumors, especially in patients with conditions like prior nephrectomy or surgical risks.
- RFA achieved a high therapeutic success rate (91%) in treating 65 tumors, although larger tumors (>5 cm) had a lower success rate (60%).
- While complications occurred in 13% of cases, with 5% classified as major, the study also highlighted its limitations, including the absence of pathological confirmation of ablation success and lack of a control group.
Article Abstract
Background: Radiofrequency ablation (RFA) is a minimally aggressive, therapeutic alternative for renal tumors. It can be an alternative to nephrectomy in patients with previous nephrectomy, bilateral tumors, von Hippel-Lindau disease, or small renal carcinomas and in those with contraindications for surgery.
Objective: To assess the effectiveness of the treatment of renal tumors by RFA in the short and medium term and to identify the possible complications and the factors that determine therapeutic success.
Design, Setting, And Participants: A retrospective review of patients with renal tumors treated with RFA between May 2005 and December 2008 was performed in a tertiary academic hospital. Patients were selected among those with previous nephrectomy, bilateral neoplasms, von Hippel-Lindau disease, surgical risk, comorbidity, advanced age, or patient's refusal to surgery. Tumors with evidence of extrarenal extension were excluded. Patients were followed up for 10-50 mo using computed tomography and magnetic resonance imaging.
Intervention: Ultrasound-guided RFA was performed on 65 tumors (range: 1.2-5.3 cm) of 58 patients using multitined electrodes.
Measurements: Incomplete ablation rate, therapeutic success rate, and complications rate.
Results And Limitations: Therapeutic success was achieved in 59 of 65 tumors (91%): 53 in a single session, 5 in two sessions, and 1 in three sessions. A significant relationship was observed between size and growth pattern of the tumor and both therapeutic success and incomplete ablation rates. Therapeutic success in tumors >5 cm was 60%. Complications were detected in 10 patients (13%); 5% were considered major complications. Limitations include the lack of pathologic studies to confirm a complete ablation and the lack of a control group to compare with the results of those who underwent nephrectomy.
Conclusions: RFA is safe and effective in renal tumors. Corticomedullary lesions and tumors >3 cm have greater possibility of incomplete ablation. In tumors >5 cm, RFA has a significant failure rate.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eururo.2009.11.025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MELANOMAS, SARCOMAS, AND RENAL METASTASES IN THE LIVER: HOW TO TREAT?
Arq Bras Cir Dig
January 2025
D'Or Institute for Research and Education, Digestive Surgery Residency Program - Rio de Janeiro (RJ), Brazil.
Liver metastases from melanomas, sarcomas, and renal tumors are less frequent. Treatment and prognosis will depend on whether they are isolated or multiple, size and location, the presence or absence of extrahepatic neoplastic disease, age, stage of the initial disease, initial treatments instituted, time of evolution, and clinical condition of the patient. Recently, a high number of oncological therapies including monotherapy or in combination, neoadjuvants or adjuvants, and immuno-oncological treatments have been developed and tested, increasing disease-free time and survival.
View Article and Find Full Text PDFPotentially paraneoplastic glomerulopathies in a Brazilian cohort: a retrospective analysis.
J Bras Nefrol
January 2025
Universidade Federal de São Paulo (UNIFESP), Departamento de Medicina, Divisão de Nefrologia, São Paulo, SP, Brazil.
Introduction: Glomerular diseases can be associated with solid or hematopoietic malignancies. The prevalence of these associations varies according to the studied glomerular disease. This study aimed to evaluate the frequency and type of neoplasms in patients with glomerular diseases as well as their clinical, laboratory, and histopathological features and the relationship with immunosuppressive therapy.
View Article and Find Full Text PDFFeasibility and safety of hyperthermic intra-peritoneal chemotherapy in patients with ovarian cancer and chronic kidney disease.
Int J Gynecol Cancer
January 2025
Division of Gynecologic Oncology, Obstetrics & Gynecology Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Objective: This study aimed to compare perioperative outcomes and progression-free and overall survival in patients with chronic kidney disease (CKD) versus those without after hyperthermic intra-peritoneal chemotherapy (HIPEC) for ovarian cancer.
Methods: This is a retrospective, single-institution cohort study of patients with ovarian cancer treated with HIPEC at the Cleveland Clinic from January 2009 to December 2022. All patients received HIPEC with cisplatin and renal protection with mannitol and furosemide.
Ferroptosis and its relationship with cancer.
Front Cell Dev Biol
January 2025
Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University, Nanjing, China.
Marked by iron buildup and lipid peroxidation, ferroptosis is a relatively new regulatory cell death (RCD) pathway. Many diseases like cancer, myocardial ischemia-reperfusion injury (MIRI), neurological disorders and acute renal failure (AKI) are corelated with ferroptosis. The main molecular processes of ferroptosis discovered yet will be presented here, along with the approaches in which it interacts with tumour-associated signaling pathways and its uses in systemic therapy, radiation therapy, and immunotherapy managing tumors.
View Article and Find Full Text PDFEvaluating the Effectiveness of a Novel Pongamia pinnata Derived Herbal Mouth-Dissolving Film for Treating Oral Disorders and Evaluating Its Anticancer Properties.
Cell Biochem Funct
February 2025
Department of Life Sciences, Hemchandracharya North Gujarat University, Patan, India.
The present study aimed to optimize a mouth-dissolving film (MDF) made from Pongamia pinnata stem bark extract to increase patient compliance and accelerate oral disease therapy. Several stem bark extracts were prepared, and karanjin was used as an herbal marker for the extracts. The ethanolic extract showed the maximum yield (12.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!